Will crizotinib cause pneumonia?

During the use of crizotinib, the side effect of pneumonia may occur, which is mainly a manifestation of interstitial lung disease (ILD)/pneumonitis.

Crizotinib is a targeted drug mainly used to treat ALK positive or ROS1 positive non-small cell lung cancer. However, based on clinical research and actual drug experience, a small number of patients may develop the side effect of ILD/pneumonitis during treatment with crizotinib. Although this side effect is uncommon, when it occurs it can have serious consequences for the patient's health.

ILD/The symptoms and manifestations of pneumonia may vary depending on individual patients, but usually include difficulty breathing, cough, fever, etc. These symptoms may gradually worsen and seriously affect the patient's quality of life. In severe cases, ILD/pneumonia may even lead to death.

To reduce the risk of ILD/pneumonia, patients need to undergo regular lung imaging examinations (such as CT scans) and pulmonary function tests during treatment with crizotinib. In addition, doctors will also pay close attention to the patient's symptom changes in order to detect and deal with any abnormalities in time.

Once a patient develops symptoms of ILD/pneumonia, doctors may take a series of measures to manage this side effect, including but not limited to suspending crizotinib treatment, giving anti-inflammatory drugs such as glucocorticoids, and performing necessary supportive treatment.

Before receiving crizotinib treatment, doctors will explain possible side effects to patients in detail, includingILD/pneumonitis. Patients should be fully aware of these risks and follow their doctor's recommendations for regular monitoring and follow-up. At the same time, if the patient develops any symptoms of discomfort during treatment, such as difficulty breathing, cough, etc., he should inform the doctor immediately for timely evaluation and treatment.